Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Pediatric PNH Patients
NCT06934967Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Primary completion
- Oct 2031
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events at 26 weeks, Maximum observed plasma concentration at Week 2 and 3 more. Started Oct 2025; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06934967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934967.